Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EPS (Basic): 2020-2025

Historic EPS (Basic) for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$2.13.

  • Lyell Immunopharma's EPS (Basic) rose 38.79% to -$2.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.32, marking a year-over-year increase of 170.84%. This contributed to the annual value of -$1.31 for FY2024, which is 40.86% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's EPS (Basic) is -$2.13, which was up 26.30% from -$2.89 recorded in Q2 2025.
  • Lyell Immunopharma's 5-year EPS (Basic) high stood at $10.52 for Q4 2024, and its period low was -$3.59 during Q2 2024.
  • Over the past 3 years, Lyell Immunopharma's median EPS (Basic) value was -$0.26 (recorded in 2023), while the average stood at -$0.27.
  • Examining YoY changes over the last 5 years, Lyell Immunopharma's EPS (Basic) showed a top increase of 5,360.00% in 2024 and a maximum decrease of 1,640.00% in 2024.
  • Lyell Immunopharma's EPS (Basic) (Quarterly) stood at -$0.18 in 2021, then surged by 83.33% to -$0.03 in 2022, then crashed by 566.67% to -$0.20 in 2023, then skyrocketed by 5,360.00% to $10.52 in 2024, then skyrocketed by 38.79% to -$2.13 in 2025.
  • Its last three reported values are -$2.13 in Q3 2025, -$2.89 for Q2 2025, and -$0.18 during Q1 2025.